BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral presentation at the European Hematology Association 2023 Congress (EHA) in Frankfurt, Germany on June 10.

Akumin Inc. announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023.

TriSalus Life Sciences® Inc., an oncology company in the process of going public through a business combination transaction with MedTech Acquisition Corporation, announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023.

AVROBIO, Inc. announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell gene therapy program for cystinosis to Novartis for $87.5 million in cash.

Parthenon Therapeutics today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from an international panel of cancer experts convened to provide an initial consensus on the role of immune exclusion in cancer.

Simcere Pharmaceutical Group Limited announced a Sponsored Research Agreement with Mass General Brigham.

Coya Therapeutics, Inc., a clinical-stage biotechnology company developing biologics intended to enhance Treg function, released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.

Castle Biosciences, Inc. announced new data demonstrating the ability of the DecisionDx®-SCC test to identify cutaneous squamous cell carcinoma tumors at a biologically high risk of metastasis in a subset of patients considered to be at a low risk of metastasis by traditional staging and Brigham and Women’s Hospital staging systems.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) will hold a video conference call on Tuesday, June 13, 2023, to update investors and analysts on the Phase 1 trial of its lead peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), for the treatment of solid tumors.

CalciMedica Inc. announced that The Nasdaq Stock Market LLC has approved CalciMedica’s application for the relisting of the Company’s common stock on the Nasdaq Capital Market.